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Abstract While the modest reduction in the primary compos-
ite outcome of myocardial infarction, stroke or cardiovascular
death in the EMPA-REG Outcomes trial was welcome, the
30–40% reductions in heart failure hospitalisation (HFH)
and cardiovascular and all-cause deaths in patients treated
with empagliflozin were highly impressive and unexpected.
In this review, we discuss briefly why cardiovascular endpoint
trials for new diabetes agents are required and describe the
results of the first four such trials to have reported, as a
precursor to understanding why the EMPA-REG Outcomes
results came as a surprise. Thereafter, we discuss potential
mechanisms that could explain the EMPA-REG Outcomes
results, concentrating on non-atherothrombotic effects. We
suggest that the main driver of benefit may derive from the
specific effects of sodium-glucose linked transporter-2
(SGLT2) inhibition on renal sodium and glucose handling,
leading to both diuresis and improvements in diabetes-
related maladaptive renal arteriolar responses. These haemo-
dynamic and renal effects are likely to be beneficial in patients
with clinical or subclinical cardiac dysfunction. The net result
of these processes, we argue, is an improvement in cardiac
systolic and diastolic function and, thereby, a lower risk of
HFH and sudden cardiac death.We also discuss whether other
drugs in this class are likely to show similar cardiovascular
benefits. Finally, areas for future research are suggested to
better understand the relevant mechanisms and to identify
other groups who may benefit from SGLT2 inhibitor therapy.
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Abbreviations
DPP-4 Dipeptidyl peptidase-4
EXAMINE Examination of Cardiovascular Outcomes
with Alogliptin versus Standard of Care
GLP-1 Glucagon-like peptide-1
HFH Heart failure hospitalisation
SAVOR-TIMI Saxagliptin Assessment of Vascular
Outcomes Recorded in Patients with
Diabetes Mellitus–Thrombolysis in
Myocardial Infarction
SGLT2 Sodium-glucose linked transporter-2
SNS Sympathetic nervous system
TECOS Trial Evaluating Cardiovascular Outcomes
with Sitagliptin
Introduction: cardiovascular endpoint trials for new
diabetes agents
Recent epidemiological studies indicate that diabetes ap-
proximately doubles cardiovascular risk [1]. It also increases
mortality risk from non-cardiovascular causes, including
premature death from cancers. Fortunately, cardiovascular
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and mortality risks have declined over recent decades, due to
reductions in atherogenic lipids, blood pressure and smoking
rates, and better glycaemia management. Greater absolute
cardiovascular benefits appear to accrue more from reducing
LDL-cholesterol and blood pressure than from intensively
targeting glycaemia [2].
Notably, the results of recent trials comparing intensive
glucose control with standard control led to some concern that
aggressive lowering of glucose levels in some individuals may
increase short-term mortality, as seen in the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) study [3], even
though meta-analyses of such trials did confirm a modest
reduction in coronary events. Furthermore, initial concerns
(now largely refuted [4]) about the cardiovascular safety of
rosiglitazone led the US Food and Drug Administration to
mandate that all new glucose-lowering agents must be tested
for cardiovascular safety in post-marketing endpoint trials.
Consequently, a multitude of such trials are ongoing. It should
be borne in mind that these trials are primarily designed to
assess cardiovascular safety and, as such, are typically
powered to demonstrate non-inferiority (defined as upper
boundary of the 95% CI of the HR<1.3) with superiority
included as a subsequent statistical test (defined as upper
boundary of the HR<1.0). Five major trials have recently
been published. Four of these trials investigated drugs that
act on the incretin pathway (three dipeptidyl peptidase-4
[DPP-4] inhibitor trials and one glucagon-like peptide-1
[GLP-1] receptor agonist trial), with the most recent being
the first sodium-glucose linked transporter-2 (SGLT2)
inhibitor trial. This short review summarises the results of
the first four trials as an important precursor to understanding
why the results of the EMPA-REG Outcomes trial took
clinicians by surprise [5]. The review then examines the
possible mechanisms responsible for the benefit observed in
EMPA-REG Outcomes.
What did the trials with DPP-4 inhibitors and GLP-1
receptor agonists show?
The four trials were not designed as glucose-lowering trials
per se since background glucose-lowering medications (other
than incretin therapy) were generally allowed to be changed
freely in both arms, in line with usual care. DPP-4 inhibitors
are glucose-lowering agents that neither increase weight nor
cause hypoglycaemia and that have negligible effects on lipids
or blood pressure (Table 1). That noted, meta-analyses of
shorter-term DPP-4 inhibitor studies seemed to suggest that
cardiovascular risk might be significantly lowered in line with
as yet unknown ‘pleiotropic’ effects.
The results of the first two DPP-4 inhibitor trials
(Saxagliptin Assessment of Vascular Outcomes Recorded in
Patients with Diabetes Mellitus [SAVOR]–Thrombolysis in
Myocardial Infarction [TIMI] 53 [6] and Examination of
Cardiovascular Outcomes with Alogliptin versus Standard of
Care [EXAMINE] [7], testing saxagliptin and alogliptin,
respectively, as add-on therapies) were presented at the
European Society of Cardiology annual meeting in
September 2014. These two trials were conducted largely in
high-risk patients (secondary prevention or acute coronary
syndrome patients) to allow rapid accumulation of cardio-
vascular events and, consequently, were short in duration
(Table 2).
The trials reported modest HbA1c differences between
treatment arms and demonstrated non-inferiority for cardio-
vascular events (SAVOR–TIMI 53, HR 1.00 [95% CI 0.89,
1.12]; EXAMINE, HR 0.96 [upper boundary of one-sided
repeated CI 1.16]). One concern was a slight but significant
increase in risk of heart failure hospitalisation (HFH) seen
with saxagliptin in the SAVOR−TIMI study. EXAMINE also
showed a higher risk of HFH [7] and, although not significant,
the pooled results of SAVOR−TIMI and EXAMINE did raise
a suspicion that this class of drugs may be associated with an
increase in the risk of heart failure. This point has since been
heavily debated and further studies or trials with these agents
are being planned specifically to examine effects on cardiac
structure and function.
The third DPP-4 inhibitor trial was the Trial Evaluating
Cardiovascular Outcomes with Sitagliptin (TECOS), which
tested sitagliptin in patients with established cardiovascular
disease [8]. The duration of this trial was somewhat longer
and the difference in HbA1c between treatment arms was
again small (Table 2). The results showed neutrality with
respect to cardiovascular outcomes (HR 0.98 [95% CI 0.88,
1.09]) and there was no evidence for an increase in HFH. The
fourth trial published in this series of new diabetes agents
tested lixisenatide, a short acting GLP-1 receptor agonist, in
patients with recent acute coronary syndrome [9]. Given that
GLP-1 receptor agonists lower not only glucose but also
weight and blood pressure [10], it was hoped that the results
would demonstrate cardiovascular benefit. Again, the trial
demonstrated non-inferiority for cardiovascular events
(HR 1.02 [95% CI 0.89, 1.17]) with no suggestion of benefit.
Similarly, HFH and mortality were unchanged.
The value of cardiovascular endpoint trials for new
glucose-lowering agents
While the availability of new glucose-lowering agents that
have been shown to be safe in robust trials has substantially
expanded the treatment options available, it appears that
demonstrating not only non-inferiority but actual clinical
benefit, in the context of falling cardiovascular event rates,
would require even larger studies with longer follow-up than
have yet been considered. Although assessing safety is
Diabetologia
critically important, trials of agents with modest effects on
HbA1c which are conducted in specific high-risk populations
(e.g. those with recent acute coronary syndrome, arguably lim-
iting the ability to impact upon major cardiovascular events
within the first year) over relatively short durations seem un-
likely to have the capacity to show benefit, even if the agent in
question is superior to standard practice. It is important to stress
that the results of Liraglutide Effect and Action in Diabetes:
Evaluation of Cardiovascular Outcome Results (LEADER;
testing liraglutide; ClinicalTrial.gov registration no.
NCT01179048 [11]) and Exenatide Study of Cardiovascular
Event Lowering Trial (EXSCEL; testing once-weekly
exenatide; ClinicalTrial.gov registration no. NCT01144338)
are eagerly awaited since they involveGLP-1 receptor agonists
that have a longer duration of action than lixisenatide and have
stronger glucose- and weight-lowering effects [12]. Hence,
the effect of GLP-1 receptor agonists on cardiovascular
outcomes should remain an open question for now.
SGLT2 Inhibitor class: EMPA-REG Outcomes
The aforementioned neutral results of trials might explain
why, when EMPA-REG Outcomes data were reported at the
EASD annual meeting in Stockholm in 2015, the audience
were highly surprised with the reductions in cardiovascular
mortality, all-cause mortality and HFH for empagliflozin vs
placebo. Could these results have been predicted based on
what we knew about the mode of action? At the level of
commonly considered risk factor changes, the answer is
no—see Table 1. While SGLT2 inhibitors lower not only
glucose but also weight and blood pressure, their effects on
lipids are mixed with parallel rises in LDL-cholesterol and
HDL-cholesterol [13]. Such risk factor patterns therefore
made it impossible to predict the net effect of SGLT2
inhibitors on cardiovascular outcomes.
EMPA-REG Outcomes tested empagliflozin at two doses
(10 and 25 mg daily) vs placebo in patients with existing
cardiovascular disease over about 3 years. In keeping with
what is known about the drug’s efficacy, active treatment
compared with placebo led to reductions in HbA1c
(by ~0.3–0.5%), weight (by ~2 kg) and systolic blood
pressure (by ~3 mmHg) without any compensatory
increase in heart rate [5]. There were also slight rises in
LDL-cholesterol and HDL-cholesterol levels as expected.
The primary outcome of this trial was the ‘MACE’ (major
adverse cardiac events) composite of death from cardio-
vascular causes, non-fatal myocardial infarction or non-fatal
stroke, recommended in theUS Food andDrugAdministration’s
guidance on evaluating new glucose-lowering agents and used in
Table 2 A simple overview of the five major diabetes trials of newer agents reported to date
Therapy Trial N Population Follow-up
duration
HbA1c difference
during follow-up (%)
Primary outcome
Saxagliptin
(DPP-4 inhibitor)
SAVOR−TIMI 53 16,492 +CVD (80%) or –CVD
at high risk (20%)
24 months 0.2–0.3% CVD death, NF MI or stroke
Alogliptin
(DPP-4 inhibitor)
EXAMINE 5,380 MI or UAwithin last
15–90 days
18 months 0.36% CVD death, NF MI or stroke
Sitagliptin
(DPP-4 inhibitor)
TECOS 14,671 +CVD 36 months 0.3% CVD death, NF MI or stroke,
hospitalisation for UA
Lixisenatide
(GLP-1R agonist)
ELIXA 6,068 MI or UAwithin last
180 days
25 months 0.27% CVD death, NF MI or stroke,
hospitalisation for UA
Empagliflozin
(SGLT2 inhibitor)
EMPA-REG
Outcomes
7,020 +CVD 37 months 0.3–0.5% CVD death, NF MI or stroke
CVD, cardiovascular disease; ELIXA, Evaluation of Lixisenatide inAcute Coronary Syndrome;MI,myocardial infarction, NF, non-fatal; UA, unstable angina
Table 1 The broad effects on
commonly considered risk factors
of differing classes of new diabe-
tes agents
Risk factor DPP-4 inhibitors GLP-1 receptor agonists SGLT2 inhibitors
Hypoglycaemia risk Low Low Low
Weight Neutral Reduced Reduced
Blood pressure Neutral Lower Lower
Lipids Neutral HDL-cholesterol ↑ /
triacylglycerols ↓
Mixed (LDL-cholesterol ↑ /
HDL-cholesterol ↑ /
triacylglycerols ↓)
Other miscellaneous
effects of potential
relevance
Increase in heart
failure in
some trials
Heart rate ↑ variably
among different GLP-1
receptor agonists
Genital infections
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most of the other trials discussed earlier. While the primary
outcome was reduced by empagliflozin (HR 0.86 [95 CI 0.74,
0.99]), myocardial infarction was not significantly reduced
(HR 0.87 [95% CI 0.70, 1.09]), although it was directionally
concordant, and stroke was non-significantly increased
(HR 1.18 [95% CI 0.89, 1.56]) despite the fall in blood pressure
[5]. The pattern of results from other pre-specified outcomes
revealed something rather different. Empagliflozin significantly
lowered death from cardiovascular causes (by 38%), HFH
(by 35%) and death from any cause (by 32%) [5]. Although
one must be cautious in interpreting these results on the basis
that they were secondary outcomes and while further trial
evidence is crucial, such a substantial reduction in all-cause death
in particular gives confidence in their validity. It was the
reduction in cardiovascular death that primarily drove the
reduction in the primary endpoint. These benefits on mortality
and HFH emerged very rapidly, almost immediately.
Reassuringly, other than the expected increase in genital
infections with empagliflozin (6.4% vs 1.8%), there was no
increase in rates of diabetic ketoacidosis, fractures or
hypoglycaemia [5]. There is now considerable interest in
determining the potential underlying mechanisms for the
EMPA-REG Outcomes findings.
What potential mechanisms could explain
the benefits?
A non-atherothrombotic explanation for the benefits is
suggested by two important aspects from the EMPA-REG
Outcomes trial: first, by substantial reductions in HFH and
cardiovascular mortality rather than any clear effect on
myocardial infarction or stroke risk; second, by the very rapid
emergence of benefit as shown by the separation of
Cumulative Incidence curves for cardiovascular mortality
and HFH following randomisation [5]. To better understand
what may have happened, we need to revisit the pathophysi-
ology of heart failure.
Heart failure is defined by the inability of the heart to
deliver sufficient oxygen to peripheral organs and clinically
as a syndrome defined by the presence of symptoms such as
ankle swelling, dyspnoea and fatigue and signs such as
elevated venous jugular pressure and pulmonary crackles. It
can arise as a result of almost any abnormality of the structure,
mechanical function or electrical activity of the heart and is the
common, end-stage, manifestation of many cardiovascular
diseases including myocardial infarction. Once heart failure
ensues, reduced systolic (contraction) and/or diastolic
(relaxation) function may lead to sodium and fluid retention,
due to renal haemodynamic changes and as a result of
activation of the renin—angiotensin—aldosterone system,
sympathetic nervous system (SNS) and other neurohumoral
systems. SNS activation occurs in an attempt to maintain
cardiac output, through increased contractility (stroke volume)
and heart rate, and redistribute blood flow (but at the expense
of enhanced systemic vasoconstriction). Heart failure is
characterised by a trajectory of deteriorating cardiac output
and declining renal function leading to fluid retention,
peripheral oedema and pulmonary congestion, which if severe
may lead to hospitalisation and treatment with intravenous
diuretic. Of course there is a strong link between heart failure
and sudden death: dilated and hypertrophied cardiac chambers
fail and fibrillate, so patients may die from either pump failure
or sudden arrhythmia.
At baseline, 10% of EMPA-REG Outcomes participants
were clinically recorded as having heart failure, and it is
likely that a further proportion of this high cardiovascular
risk population had subclinical cardiac dysfunction. The
results of the trial suggest that empagliflozin somehow
interrupts one or more of the mechanisms involved in the
progression of cardiac dysfunction mentioned above. We
postulate that the relevant effect or effects of empagliflozin
may involve the mechanisms included in the text box
below.
Possible mechanisms for effects of empagliflozin on
reduced risk of heart failure
• Diuresis leading to reduced extracellular fluid volume
(reflected in a rise in haematocrit) and cardiac pre-load, an
action similar to that obtained with conventional diuretics
• One or more peripheral vascular actions leading to
reduced cardiac pre- and afterload and lower systolic
blood pressure, and thereby providing an important
alleviation of cardiac stress
• Improved cardiac metabolism, enhancing diastolic and
systolic function. Of interest, SGLT1 rather than SGLT2
receptors have been found in cardiac tissue so direct
effects of empagliflozin on cardiac function appear
unlikely
Less predictable mechanisms that could contribute to a
reduced risk of heart failure
• Suppression of adverse neurohumoral systems, although
the lack of increase in heart rate suggests no further SNS
activation
• Reduction in myocardial ischaemia, unrecognised/silent
myocardial infarction or other causes of cardiomyocyte
necrosis
• Reduction in pathological growth (hypertrophy and
fibrosis)
• Reduction in arrhythmias
• Greater use of other agents in placebo arm that cause
weight gain, or directly increase fluid load
(thiazolidinediones)
Diabetologia
Relevance of blood pressure and renal effects
Whether the blood pressure-lowering effects of empagliflozin
alone can explain the observed benefit is worthy of
consideration since reducing blood pressure (even by small
amounts) can influence heart failure risks, although not
necessarily as rapidly as seen in EMPA-REG Outcomes.
Empagliflozin also induces a considerable diuresis, with early
loss of urinary glucose in particular and subsequently of
sodium as reflected by a sizeable increase in the haematocrit
(~4%) compared with placebo, and certainly adequate dosage
of diuretics can rapidly reduce heart failure risks, or risks for
HFH [14]. Notably, in the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT), in
which just over one-third of patients had type 2 diabetes,
use of the thiazide diuretic chlorthalidone was associated
with a 28% (95% CI 20, 34) lower risk of heart failure
compared with amlodipine despite only a 0.8 mmHg difference
in achieved systolic blood pressure [15]. That noted, there were
no differences in other vascular endpoints.
We consider that the cardiovascular benefit of
empagliflozin is related to the manner in which it induces
diuresis (both glucose and sodium losses), notably with a
reduction in the progression to renal failure and with a slowing
in the deterioration of renal function. Type 2 diabetes is
typified by upregulated SGLT2 tubular transporters and
increased tubular glucose reabsorption, along with sodium
reabsorption in the proximal renal tubules, leading to
decreased sodium delivery to the macula densa, vasodilatation
of the afferent arteriole with vasoconstriction of the efferent
arteriole and resultant intraglomerular hypertension. The
combination of the diuretic effect and increased sodium
delivery to the macula densa [16], thereby helping to address
the maladaptive arteriolar responses, may explain the finding
of both cardiac and renal benefit of SGLT2 inhibition. In
essence, improving renal sodium and glucose handling, with
subsequent reductions in fluid burden especially in individuals
with or susceptible to cardiac dysfunction, may have been the
key driver underlying the benefits seen in EMPA-REG
Outcomes (Fig. 1). There is a need for detailed mechanistic
studies incorporating state of the art imagining techniques to
better determine the full cardiovascular actions of
empagliflozin and other SGLT2 inhibitors in patients with
diabetes. Such studies should involve a range of diabetes
Urinary glucose loss
Urinary sodium loss
+ Diuresis 
(+ energy loss, weight 
reduction?)
KIDNEY: SGLT2 inhibition
Glucose and sodium        
reabsorption in proximal
tubule
(improved tubular glomerular 
feedback)
CIRCULATION
Intravascular/ECF volume
Haematocrit
(thus, haemoconcentration)
Systolic blood pressure
HEART (+ lungs)
Cardiac afterload
Cardiac pre-load
Myocardial oxygen supply
± Improved cardiac metabolism? 
Improvement in systolic and 
diastolic dysfunction
Likelihood of pulmonary            
congestion
Lower risk of HFH
Lower risk of fatal arrhythmias 
Improved renal function
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Fig. 1 Potential pathway linking empagliflozin (and possibly other
SGLT2 inhibitors) with lower risks for HFH (and, linked to this, death
due to cardiovascular disease). By increasing fluid losses via urinary
glucose and sodium losses (1), intravascular volumes and systolic blood
pressure are reduced and there is a significant rise in haematocrit (2).
These latter effects may also be, to a small extent, assisted by weight loss.
These changes in turn lessen cardiac stressors (pre- and afterload) and
may also help improve myocardial oxygen supply (3). The net result is a
likely improvement in cardiac systolic and diastolic function, lessening
chances of pulmonary congestion, thus lowering risks of HFH and fatal
arrhythmias. These cardiac function benefits will, in turn, feed back to
improve renal blood flow and function (4). In this way, the cardio-renal
axis is improved at a number of levels with SGLT2 inhibitor therapy
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patients with and without cardiovascular disease and with and
without existing heart failure. In addition, major trials will be
required to establish whether SGLT2 inhibitor therapy, with its
proposed novel diuretic-like action, might provide clinically
meaningful benefit in lower-risk populations.
Other important lessons from EMPA-REG
Outcomes
There have been secular decreases in myocardial infarction
and stroke rates in patients with diabetes, reflecting con-
siderable improvements in lipid and blood pressure manage-
ment over the last two decades. Indeed, in EMPA-REG
Outcomes, more than 75% of patients were on statins and
around 95% on antihypertensive agents at baseline, and
baseline LDL-cholesterol and blood pressure results would
be considered excellent in most clinical settings. However,
heart failure remains an under-recognised complication of
diabetes and one which carries a poor prognosis [17]. In a
recent observational analysis of patients with diabetes, heart
failure was found to be the second-most common type of first
cardiovascular disease presentation (after peripheral vascular
disease) [18]. In diabetes, the pathogenesis of heart failure is
likely to be multi-factorial given the presence of risk factors
including dysglycaemia, coronary heart disease, hypertension,
obesity, renal dysfunction and others. It is therefore increas-
ingly apparent that therapeutic approaches that also reduce the
development and progression of heart failure (i.e. beyond
atherothrombotic targeting) are crucial in patients with
diabetes.
Unanswered questions
Why stroke risk in EMPA-REG Outcomes did not decline on
empagliflozin, when the risk of stroke is normally very sensi-
tive to reductions in blood pressure, is not clear. Meta-analysis
of trials suggests that stroke risks can be significantly lowered
even when baseline systolic blood pressure is <140 mmHg
[19] and so further investigations are clearly required. That
the haemoconcentration effect of SGLT2 inhibition may have
balanced out the blood pressure-lowering effect is plausible,
and results from other major ongoing trials will yield valuable
data.
Will other SGLT2 inhibitors give the same results
as EMPA-REG Outcomes?
If we assume that the explanations for the benefit of
empagliflozin revolve around its effects principally on
diuresis (driven by promoting both glucose and sodium loss)
and via blood pressure reductions, then other SGLT2 inhibi-
tors should yield directionally similar outcomes. That noted,
available SGLT2 inhibitors have differential specificities for
SGLT2 and SGLT1 [20], the relevance of which is not clear
for the moment. Fortunately, we will not have to wait too long
before know the results of the ongoing trials for canagliflozin
(Canagliflozin Cardiovascular Safety Assessment [CANVAS]
due to be completed in 2017; ClinicalTrial.gov registration no.
NCT01032629) [21] and dapagliflozin (Dapagliflozin Effect
on CardiovascuLAR Events [DECLARE]-TIMI 58, due to be
completed in 2019; ClinicalTrial.gov registration no.
NCT01730534 [www.timi.org/index.php?page=declare-timi-58,
accessed 1 April 2016]).
Summary
The effects of empagliflozin on important secondary end-
points in EMPA-REG Outcomes, namely HFH, cardiovascu-
lar and all-cause death, were unexpected. The rapid emer-
gence of these benefits points strongly towards non-
atherothrombotic mechanisms, perhaps principally
haemodynamic effects. Further mechanistic studies will be
needed to identify these mechanisms and further clinical trials
of SGLT2 inhibitors in patients with and without heart failure,
with and without cardiovascular disease and, potentially, with
and without diabetes, will likely ensue. Finally, we will also
shortly know whether these findings are common to other
drugs in the class. It appears that a new era in diabetes–
cardiovascular research has emerged.
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